Public Employees Retirement Association of Colorado Cuts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Public Employees Retirement Association of Colorado trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,384 shares of the biopharmaceutical company’s stock after selling 491 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Alnylam Pharmaceuticals were worth $3,252,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after buying an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after purchasing an additional 201,784 shares during the period. Capital International Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after purchasing an additional 64,560 shares during the period. Capital Research Global Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after purchasing an additional 214,908 shares during the period. Finally, Avoro Capital Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 9.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 1,111,111 shares of the biopharmaceutical company’s stock worth $212,678,000 after purchasing an additional 100,000 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALNY has been the subject of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday. Needham & Company LLC increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, September 9th. Finally, The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $279.14.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 2,103 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $485,771.97. Following the completion of the transaction, the chief marketing officer now owns 15,609 shares in the company, valued at $3,605,522.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now owns 80,534 shares in the company, valued at $18,602,548.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 2,103 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $485,771.97. Following the completion of the transaction, the chief marketing officer now directly owns 15,609 shares in the company, valued at approximately $3,605,522.91. The disclosure for this sale can be found here. In the last three months, insiders have sold 70,698 shares of company stock worth $18,497,434. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $273.88 on Monday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $287.55. The company has a 50 day simple moving average of $260.11 and a two-hundred day simple moving average of $199.42. The company has a market capitalization of $34.64 billion, a price-to-earnings ratio of -102.19 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same period in the prior year, the business posted ($2.21) EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.